Med undtagelse af en 13% stigning i Cmax for sildenafil var der ikke ændringer i de farmakokinetiske parametre for hverken sildenafil, N- desmetyl- sildenafil eller ambrisentan.
With the exception of a 13% increase in sildenafil Cmax following co-administration with ambrisentan, there were no other changes in the pharmacokinetic parameters of sildenafil, N-desmethyl-sildenafil and ambrisentan.